학술논문
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group
Document Type
Artikel
Author
Partanen, A; Waage, A; Peceliunas, V; Schjesvold, F; Anttila, P; Saeily, M; Uttervall, K; Putkonen, M; Carlson, K; Haukas, E; Sankelo, M; Szatkowski, D; Hansson, M; Marttila, A; Svensson, R; Axelsson, P; Lauri, B; Mikkola, M; Karlsson, C; Abelsson, J; Ahlstrand, E; Sikioe, A; Klimkowska, M; Matuzeviciene, R; Fenstad, MH; Ilveskero, S; Pelliniemi, TT; Nahi, H; Silvennoinen, R
Source
Cancers. 16(5)
Subject
Language
English
English
English
ISSN
2072-6694